A Study of Depemokimab in Participants of 6 to 11 Years of Age
Public ClinicalTrials.gov record NCT07671001. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Open-label Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Depemokimab (GSK3511294) Administered Subcutaneously as Add on Maintenance Treatment of Asthma With Type 2 Inflammation Characterised by an Eosinophilic Phenotype in Participants Aged 6 to 11 Years Old
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is aimed at assessing depemokimab as an add-on medicine for the treatment of asthma with type-2 inflammation in participants of 6 to 11 years of age. This study will test how the body processes depemokimab, how the drug works in the body, and its safety and tolerability.
Study identification
- NCT ID
- NCT07671001
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 34 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 6 Years to 11 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 24, 2026
- Primary completion
- Feb 28, 2027
- Completion
- Nov 23, 2028
- Last update posted
- Aug 25, 2026
2026 – 2028
United States locations
- U.S. sites
- 3
- U.S. states
- 3
- U.S. cities
- 3
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Mobile | Alabama | 36608 | Recruiting |
| GSK Investigational Site | Colorado Springs | Colorado | 80923 | Recruiting |
| GSK Investigational Site | Watertown | South Dakota | 13601 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Asthma trials
Other public records listing Asthma. Sorted by last update posted; newest first. Not a recommendation.
- NCT07792395: Ginger's Therapeutic Potential in Asthma Not yet recruiting
- NCT07792330: Asthma Lung Sounds With Wearable Stethoscope Not yet recruiting
- NCT07772921: A Study to Learn About the Study Medicine Called Tilrekimig in People With Severe Asthma Not yet recruiting
- NCT07444567: Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment Recruiting
- NCT01449409: Reduce IDentified UNcontrolled Asthma Active, not recruiting
- NCT07712393: A Comparative Study to Investigate the Difference in Blood Levels of Two Different Formulations of GSK5784283 Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07671001, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 25, 2026 · Synced Aug 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07671001 live on ClinicalTrials.gov.